Compare
VivoSim Labs, Inc. vs aTYR PHARMA INC vs AIM ImmunoTech Inc. vs Inmune Bio, Inc.
| Latest fiscal year | VivoSim Labs, Inc. VIVS | aTYR PHARMA INC ATYR | AIM ImmunoTech Inc. AIM | Inmune Bio, Inc. INMB |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $131.0K | $190.0K | $88.0K | $50.0K |
| Revenue growth (YoY) | -9.0% | -19.1% | -48.2% | +257.1% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$13.84M | -$74.12M | -$13.96M | -$45.93M |
| EPS (Diluted) | -$5.35 | -$0.80 | -$8.62 | -$1.86 |
| Operating cash flow | -$10.83M | -$61.99M | -$10.96M | -$22.58M |
| Free cash flow | -$10.83M | -$62.06M | n/a | -$23.62M |
| Cash & equivalents | $5.02M | $10.74M | $2.98M | $24.75M |
| Total assets | $7.39M | $93.00M | $5.78M | $32.35M |
| Total liabilities | $8.48M | n/a | $15.56M | $8.83M |
| Shareholders' equity | -$1.10M | $67.48M | -$9.78M | $23.52M |
| Return on year-end equity | n/a | -109.8% | n/a | -195.3% |
| Shares outstanding | 2.89M | 98.03M | 3.07M | 26.59M |
Revenue, most recent five fiscal years
| Fiscal year | VivoSim Labs, Inc. | aTYR PHARMA INC | AIM ImmunoTech Inc. | Inmune Bio, Inc. |
|---|---|---|---|---|
| Latest | $131.0K Ended 2026-03-31 | $190.0K Ended 2025-12-31 | $88.0K Ended 2025-12-31 | $50.0K Ended 2025-12-31 |
| 1 year earlier | $144.0K Ended 2025-03-31 | $235.0K Ended 2024-12-31 | $170.0K Ended 2024-12-31 | $14.0K Ended 2024-12-31 |
| 2 years earlier | $109.0K Ended 2024-03-31 | $353.0K Ended 2023-12-31 | $202.0K Ended 2023-12-31 | $155.0K Ended 2023-12-31 |
| 3 years earlier | $370.0K Ended 2023-03-31 | $10.39M Ended 2022-12-31 | $141.0K Ended 2022-12-31 | $374.0K Ended 2022-12-31 |
| 4 years earlier | $1.50M Ended 2022-03-31 | $0 Ended 2021-12-31 | $135.0K Ended 2021-12-31 | $181.0K Ended 2021-12-31 |